Thursday, Jul 11, 2002
Front Page |
Southern States |
Other States |
Advts: Classifieds | Employment | Obituary |
These products are now under the purview of WHO approved list of anti-AIDs drugs, according to a release.
Ranbaxy will now become a pre-qualified supplier of these products to the U.N. agency. These products will be manufactured at the company's plant at Dewas (Central India) which has been approved by WHO, U.S. FDA, U.K. MCA, South Africa-MCC, and Australian-TGA.
The company has developed a range of generic anti retrovirals (ARVs). It markets its anti-AIDs range of products in several countries. African governments have shown interest in sourcing ARVs from Ranbaxy.
In the Indian market, at present, there are ten products available with more in the pipeline.
With this, Ranbaxy can offer sufficient drugs to construct several first line HAART (highly active anti retroviral therapy) regimens.
The company has one of the largest range of bio-equivalent generic ARVs, namely, danosine, Lamivudine, Lamivudine plus Stavudine, Lamivudine plus Zidovudine, Stavudine, Zidovudine.
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |
Copyright © 2002, The
Hindu. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of